NEW YORK: Moderna Inc executives called on investors to wait for more data amid a sharp selloff in its shares on Friday, after early data showed its mRNA-based flu vaccine was no better than already approved shots in the market.
The company's shares tumbled 10% after its investor presentation showed antibody levels of its vaccine against all four strains of the influenza virus in an early-stage study were not as robust in older people as Sanofi's Fluzone HD.
Already a subscriber? Log in
Get 20% OFF The Star Digital Access
Cancel anytime. Ad-free. Unlimited access with perks.
